Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Catalent 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Catalent 3Q

Oral Technologies drive growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent
 
3Q Revenues: $446.6 million (+8%)

3Q Earnings: $31.5 million (earnings were $6.7 million 3Q14)

YTD Revenues: $1.3 billion (+1%)

YTD Earnings: $58.5 million (loss of $11.0 million YTD14)

Comments: Growth was driven by the Oral Technologies segment ($284.0 million, +10% at constant currency) and increased demand for analytical services integrated operations within its Development and Clinical Services segment with $103.7 million for the quarter, up 4% at constant currency. Revenue from the Medication Delivery Solutions segment was $61.2 million, up 2% at constant currency. In the quarter, the company acquired Pharmapak Technologies, and completed a large-scale expansion at the Winchester, KY manufacturing facility.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics